. 2005 Oct;91(10):1265–1270. doi: 10.1136/hrt.2004.048314

Table 3.

Randomised controlled trials of nocturnal respiratory support in patients with OSAHS associated with CHF

Trial	Patient characteristics			Intervention	Duration of treatment	No of patients	Cardiovascular outcomes
Trial	CHF cause	NYHA class	Baseline LVEF (%)	Intervention	Duration of treatment	No of patients	Cardiovascular outcomes
Kaneko et al⁵⁵	ICM, DCM	2.3	25.0	CPAP	1 month	24	8.8% increase in LVEF, reduced LVESD, reduced heart rate and SBP
Mansfield et al⁵⁶	Not stated	2.2	37.3	CPAP	3 months	55	5% increase in LVEF, reduced fatigue and overnight urinary noradrenaline excretion, increased disease mastery and emotional wellbeing (CHFQ)

CHFQ, Guyatt chronic heart failure questionnaire; CPAP, continuous positive airway pressure; DCM, dilated cardiomyopathy; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; NYHA, New York Heart Association; SBP, systolic blood pressure.